secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001576280-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B
------------------------------------------------------------------------------

- Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.
- Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.
- Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.
- 2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.
- Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/0001576280-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/gh-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001576280-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer